NCT06589804 2026-04-17Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentNational Cancer Institute (NCI)Phase 3 Recruiting158 enrolled
NCT05232851 2026-04-14A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx CancerMayo ClinicPhase 1/2 Active not recruiting20 enrolled 11 charts
NCT04520711 2026-04-13Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)Providence Health & ServicesPhase 1 Active not recruiting24 enrolled
NCT05172258 2026-04-13Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckNational Cancer Institute (NCI)Phase 2 Active not recruiting52 enrolled
NCT07222566 2026-04-08Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerPfizerPhase 3 Recruiting1,410 enrolled